M
Mayumi Ueyama
Researcher at Tokyo Medical and Dental University
Publications - 8
Citations - 396
Mayumi Ueyama is an academic researcher from Tokyo Medical and Dental University. The author has contributed to research in topics: Alpha interferon & Interferon. The author has an hindex of 8, co-authored 8 publications receiving 364 citations.
Papers
More filters
Journal ArticleDOI
Antiviral effects of the interferon-induced protein guanylate binding protein 1 and its interaction with the hepatitis C virus NS5B protein.
Yasuhiro Itsui,Naoya Sakamoto,Sei Kakinuma,Mina Nakagawa,Yuko Sekine-Osajima,Megumi Tasaka-Fujita,Yuki Nishimura-Sakurai,Gouki Suda,Yuko Karakama,Kako Mishima,Machi Yamamoto,Takako Watanabe,Mayumi Ueyama,Yusuke Funaoka,Seishin Azuma,Mamoru Watanabe +15 more
TL;DR: Binding of the HCV‐NS5B protein to GBP‐1 countered the antiviral effect by inhibition of its GTPase activity, which may contribute to resistance to innate, IFN‐mediated antiviral defense and to the clinical persistence of HCV infection.
Journal ArticleDOI
Analysis of Interferon Signaling by Infectious Hepatitis C Virus Clones with Substitutions of Core Amino Acids 70 and 91
Yusuke Funaoka,Naoya Sakamoto,Goki Suda,Yasuhiro Itsui,Mina Nakagawa,Sei Kakinuma,Takako Watanabe,Kako Mishima,Mayumi Ueyama,Izumi Onozuka,Sayuri Nitta,Akiko Kitazume,Kei Kiyohashi,Miyako Murakawa,Seishin Azuma,Kiichiro Tsuchiya,Mamoru Watanabe +16 more
TL;DR: It is shown that HCV R70 and L91 core mutants were resistant to interferon in vitro, and the resistance may be induced by IL-6-induced upregulation of SOCS3, and those mechanisms may explain clinicalinterferon resistance of HCV core mutants.
Journal ArticleDOI
Cholestatic liver fibrosis and toxin-induced fibrosis are exacerbated in matrix metalloproteinase-2 deficient mice
Izumi Onozuka,Sei Kakinuma,Akihide Kamiya,Masato Miyoshi,Naoya Sakamoto,Kei Kiyohashi,Takako Watanabe,Yusuke Funaoka,Mayumi Ueyama,Mina Nakagawa,Naohiko Koshikawa,Motoharu Seiki,Hiromitsu Nakauchi,Mamoru Watanabe +13 more
TL;DR: It is suggested that MMP-2 suppresses tissue inhibitor of metalloproteinase 1 up-regulation during liver fibrosis, and that myofibroblastic change of hepatic stellate cells was promoted in M MP-2 deficient liver.
Journal ArticleDOI
Association of IL28B variants with response to pegylated‐interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b
Naoya Sakamoto,Mina Nakagawa,Yasuhito Tanaka,Yuko Sekine-Osajima,Mayumi Ueyama,Masayuki Kurosaki,Nao Nishida,Akihiro Tamori,Nishimura-Sakurai Yuki,Yasuhiro Itsui,Seishin Azuma,Sei Kakinuma,Shuhei Hige,Yoshito Itoh,Eiji Tanaka,Yoichi Hiasa,Namiki Izumi,Katsushi Tokunaga,Masashi Mizokami,Mamoru Watanabe +19 more
TL;DR: Interleukin 28B polymorphism affects responses to PEG‐IFN‐based treatment in difficult‐to‐treat HCV patients, and both rapid and sustained virological responses were associated significantly with IL28B alleles in patients with genotype 2b.
Journal ArticleDOI
Comparison of HCV-associated gene expression and cell signaling pathways in cells with or without HCV replicon and in replicon-cured cells
Yuki Nishimura-Sakurai,Naoya Sakamoto,Kaoru Mogushi,Satoshi Nagaie,Mina Nakagawa,Yasuhiro Itsui,Megumi Tasaka-Fujita,Yuko Onuki-Karakama,Goki Suda,Kako Mishima,Machi Yamamoto,Mayumi Ueyama,Yusuke Funaoka,Takako Watanabe,Seishin Azuma,Yuko Sekine-Osajima,Sei Kakinuma,Kiichiro Tsuchiya,Nobuyuki Enomoto,Hiroshi Tanaka,Mamoru Watanabe +20 more
TL;DR: Comprehensive gene expression and pathway analyses show that lipid biosynthesis pathways are crucial to support proficient virus replication and these metabolic pathways could constitute novel antiviral targets against HCV.